Teva Pharmaceutical Indu... Aktie - TEV

Professionelle Tools für Privatanleger.

Premium

Current Price

15,70

Gebot

15,55

Fragen

15,80

Volumen

6.271

15,85 Tagesbereich 16,20

11,50 52-Wochen-Bereich 22,00

Marktkapitalisierung

17,801B

Handelsende

16,05

Handelsbeginn

16,00

Letzte Trade

16.149999

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

18.498

Ausgegebene Aktien

1.133.838.689

Dividendenrendite

Kurs-Gewinn-Verhältnis

-11,41

Gewinn pro Aktie (EPS)

-1,45

Erlöse

16,54B

Nettogewinn

-1,64B

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.tevapharm.com

Hauptsitz

Tel Aviv, Center, Isr

Gegründet

1901

Teva Pharmaceutical Industries Ltd is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker TEV. The last closing price for Teva Pharmaceutical Indu... was 16,05 €. Over the last year, Teva Pharmaceutical Indu... shares have traded in a share price range of 11,50 € to 22,00 €.

Teva Pharmaceutical Indu... currently has 1.133.838.689 shares in issue. The market capitalisation of Teva Pharmaceutical Indu... is 18,20 € billion. Teva Pharmaceutical Indu... has a price to earnings ratio (PE ratio) of -11.41.

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals...

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension...

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in...

Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern

Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern AMSTERDAM, Feb. 21, 2025 (GLOBE...

Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?

Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ? AMSTERDAM, 21...

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. In October 2024, the U.S. Food and Drug Administration...

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept...

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria®...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.85	-5.13595166163	16.55	16.8	15.55	7570	16.00068546	DE
4	-2.199999	-12.2904978933	17.899999	18.35	15.3	11687	16.17527521	DE
12	-1.3	-7.64705882353	17	22	15.3	18498	19.10454083	DE
26	-0.949999	-5.70570004238	16.649999	22	15.25	13567	17.98644047	DE
52	3.45	28.1632653061	12.25	22	11.5	15560	15.94929712	DE
156	6.76	75.615212528	8.94	22	7.58	17678	13.52985367	DE
260	6.76	75.615212528	8.94	22	7.58	17678	13.52985367	DE

TEV - Frequently Asked Questions (FAQ)

What is the current Teva Pharmaceutical Indu... share price?

The current share price of Teva Pharmaceutical Indu... is 15,70 €

How many Teva Pharmaceutical Indu... shares are in issue?

Teva Pharmaceutical Indu... has 1.133.838.689 shares in issue

What is the market cap of Teva Pharmaceutical Indu...?

The market capitalisation of Teva Pharmaceutical Indu... is EUR 18,2B

What is the 1 year trading range for Teva Pharmaceutical Indu... share price?

Teva Pharmaceutical Indu... has traded in the range of 11,50 € to 22,00 € during the past year

What is the PE ratio of Teva Pharmaceutical Indu...?

The price to earnings ratio of Teva Pharmaceutical Indu... is -11,41

What is the cash to sales ratio of Teva Pharmaceutical Indu...?

The cash to sales ratio of Teva Pharmaceutical Indu... is 1,13

What is the reporting currency for Teva Pharmaceutical Indu...?

Teva Pharmaceutical Indu... reports financial results in USD

What is the latest annual turnover for Teva Pharmaceutical Indu...?

The latest annual turnover of Teva Pharmaceutical Indu... is USD 16,54B

What is the latest annual profit for Teva Pharmaceutical Indu...?

The latest annual profit of Teva Pharmaceutical Indu... is USD -1,64B

What is the registered address of Teva Pharmaceutical Indu...?

The registered address for Teva Pharmaceutical Indu... is 124 DVORA HANEVI’A ST, TEL AVIV, CENTER, 6944020

What is the Teva Pharmaceutical Indu... website address?

The website address for Teva Pharmaceutical Indu... is www.tevapharm.com

Which industry sector does Teva Pharmaceutical Indu... operate in?

Teva Pharmaceutical Indu... operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
O1YBinah Capital Group Inc	3,18 € (81,71%)	7,65k
E3O1Nexoptic Technology Corp	0,0195 € (62,50%)	5,81k
ATYArtemis Resources Limited	0,008 € (45,45%)	100k
4XNXunlei Ltd	3,92 € (43,07%)	8,09k
7S20Scotch Creek Ventures Inc	0,0475 € (41,79%)	1.000
OE6Ibotta Inc	33,00 € (-45,45%)	1,27k
3J0Digimarc Corporation	15,00 € (-41,86%)	1,78k
W4VAlphaGen Intelligence Corp	0,0075 € (-37,50%)	22k
NL8Genesis Ai Corp	0,0122 € (-34,41%)	2k
TD5ATandem Diabetes Care Inc	21,05 € (-34,32%)	3,62k
3CPXiaomi Corporation	6,97 € (0,84%)	9,47M
D7GNel ASA	0,1991 € (-0,70%)	3,79M
TKAThyssenkrupp AG	7,698 € (2,39%)	3,17M
DMJDynaCERT Inc	0,109 € (-1,36%)	2,55M
POQ88 Energy Limited	0,0012 € (-0,01%)	2,21M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Teva Pharmaceutical Industries Ltd (TEV)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Teva Pharmaceutical Industries Ltd

TEV Neueste Nachrichten

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern

Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

TEV - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Teva Pharmaceutical Industries Ltd (TEV) Börsenkurse

Teva Pharmaceutical Industries Ltd (TEV)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Teva Pharmaceutical Industries Ltd

TEV Neueste Nachrichten

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern

Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

TEV - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen